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Immune recognition mediated by the activating receptor NKG2D plays an important role
for the elimination of stressed cells, including tumors and virus-infected cells. On the other
hand, the ligands for NKG2D can also be shed into the sera of cancer patients where they
weaken the immune response by downmodulating the receptor on effector cells, mainly
NK andT cells. Although both families of NKG2D-ligands, major histocompatibility complex
class I-related chain (MIC) A/B and UL16 binding proteins (ULBPs), are related to MHC
molecules and their expression is increased after stress, many differences are observed
in terms of their biochemical properties and cell trafﬁcking. In this paper, we summarize
the variety of NKG2D-ligands and propose that selection pressure has driven evolution of
diversity in their trafﬁcking and shedding, but not receptor binding afﬁnity. However, it is
also possible to identify functional properties common to individual ULBP molecules and
MICA/B alleles, but not generally conserved within the MIC or ULBP families.These charac-
teristics likely represent examples of convergent evolution for efﬁcient immune recognition,
but are also attractive targets for pathogen immune evasion strategies. Categorization of
NKG2D-ligands according to their biological features, rather than their genetic family, may
help to achieve a better understanding of NKG2D-ligand association with disease.
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IMMUNE ACTIVATION THROUGH NKG2D
The activation of the immune system mediated by engagement
of NKG2D with its ligands is a crucial step in the regulation
of both innate and adaptive immune responses. The promiscu-
ous binding of a single receptor, NKG2D, to a set of related, but
diverse proteins is remarkable and there has been much specula-
tionon the evolution and functional signiﬁcance of this diversity of
NKG2D-ligands. The most widely accepted hypothesis to explain
the existence of many NKG2D-ligands is that they have appeared
during the evolutionof the immune system in response to selection
pressures exerted by pathogens or cancer (Eagle and Trowsdale,
2007). However, for this hypothesis to be valid there must be
signiﬁcant differences in the biochemistry and cell biology of the
distinct NKG2D-ligands so that at least some ligands can still reach
the cell surface despite the blockade of different cellular pathways
in pathogen-infected or malignant cells. Initially, the different
forms of membrane anchoring of the major histocompatibility
complex class I-related chain (MIC)A/B andUL16bindingprotein
(ULBP) 1–3 molecules [the former, transmembrane (TM); the lat-
ter, glycosyl-phosphatidyl-inositol (GPI)-anchored] were thought
to lead to differences in the cell biology of these proteins. However,
identiﬁcation of more ULBP genes and recent experiments study-
ing the biochemistry and cell biology of various members of the
two families of NKG2D-ligands have revealed common functional
properties that are conserved between particular ULBP molecules
and MIC alleles, but not within the different alleles at the MICA/B
locus or the ULBP family. Those features shared between MICs
and ULBPs may well represent examples of convergent evolu-
tion, presumably for reasons of maximal efﬁciency of immune
recognition. On the other hand, these common features have the
disadvantage of being attractive targets for pathogen immune eva-
sion strategies. These observations suggest that the classiﬁcation
of NKG2D-ligands needs to be revisited and that consideration
of similarities and differences between MIC and ULBP molecules
may help to understand the biology of these proteins and therefore
the impact of NKG2D-ligand expression on disease.
THE NKG2D RECEPTOR
NKG2D is a type II TM protein that belongs to the C lectin-like
family and is encoded on chromosome 12 in humans (Houchins
et al., 1991), mapping within the NK gene complex and in the
syntenic chromosome 6 in mice (Brown et al., 1997; for review,
see Champsaur and Lanier, 2010). It is expressed as a homod-
imer on all NK cells and, in humans, it is also constitutively
expressed on CD8+ αβ and γδ T cells from peripheral blood
and intestinal intraepithelium (for review, see Raulet, 2003; Chan
et al., 2006). Recently, it has also been described that expression of
the NKG2D receptor can be induced on a small subset of CD4+
T cells (Groh et al., 2006; Saez-Borderias et al., 2006). NKG2D
mediates both activating and co-stimulatory signals. In NK cells,
NKG2D ligation is sufﬁcient to trigger cell activation, whereas
when expressed in CD8+ T cells, the interaction of the receptor
with its ligands has a co-stimulatory function, similar to CD28.
This effect is mediated through enhancement of cytokine produc-
tion as well as signals that activate TCR driven cytotoxicity, but it
is not sufﬁcient to activate target cell lysis in the absence of TCR
engagement (Bauer et al., 1999; Jamieson et al., 2002; Snyder et al.,
2004), unless T cells have been previously activated by culture
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in vitro with IL-2 (Verneris et al., 2004). Consistent with these
data, studies on intestinal intraepithelial lymphocytes incubated
with IL-15, mimicking the conditions of coeliac disease, demon-
strated that these lymphocytes are able to produce IL-10 and
interferon (IFN)-γ after NKG2D ligation without TCR engage-
ment (Meresse et al., 2004; Ebert, 2005). Indeed, NKG2D+ CD4+
T cells, not present in healthy individuals, have been reported to
be involved in the patho-physiology of several immune-mediated
diseases such as rheumatoid arthritis (Groh et al., 2003), Crohn’s
disease (Allez et al., 2007), Wegener’s granulomatosis (Capraru
et al., 2008), and human cytomegalovirus (HCMV) infection
(Saez-Borderias et al., 2006).
The extracellular domain of the NKG2D receptor is involved in
the interactionwith its diverse ligands and its cytoplasmic tail lacks
classic signaling sequences. Thus, an adaptor molecule is required
to transduce the activation induced by ligand–receptor interac-
tion. NKG2D has a charged amino-acid residue in its TM domain
that mediates interaction with a complementary-charged amino-
acid in the signaling polypeptide: DAP10 in humans (Wu et al.,
1999) and either DAP10 or DAP12 in mice (Gilﬁllan et al., 2002).
DAP10 is a TM signaling polypeptide that has an intracellular
YxxM motif, which, upon tyrosine phosphorylation, couples the
NKG2D/NKG2D-ligand complex to the phosphatidylinositol-3-
kinase (PI3K)/Grb-2/Vav1 pathway (Upshaw et al., 2006), leading
to activation. Noteworthy, the recruitment of both the effector
molecule Vav-1 and the intermediate molecule Grb2 to DAP10
are necessary for cell-mediated cytotoxicity. Cell surface expres-
sion of the receptor can be modulated by cytokine secretion in
the tissue microenvironment as well as by the presence of soluble
NKG2D-ligands. For example, the γ-chain cytokines IL-2 and
IL-15 rapidly increase the expression of both NKG2D and DAP10
on CD8+ T cells (Dhanji and Teh, 2003; Verneris et al., 2004;
Dann et al., 2005; Maasho et al., 2005). Similarly, IL-15 in com-
bination with TNF-α can induce the expression of NKG2D in the
CD4+NKG2D+ T cells found in patients with rheumatoid arthri-
tis mentioned previously (Groh et al., 2003). Moreover, IL-15 and
IL-7 can maintain NKG2D surface expression after NKG2D co-
stimulation of TCR activated CD8+ T cells (Maasho et al., 2005).
On the other hand, exposure to other cytokines can produce a
downmodulation of theNKG2Dreceptor. IL-21, producedby acti-
vated CD4+ T cells, which by its own activates both CD8+ T cells
and NK cells promoting NKG2D-dependent killing of tumor cells
(Takaki et al., 2005), when secreted in combination with IL-2
induces downregulation of NKG2D, thus silencing of the receptor-
mediated immunosurveillance (Burgess et al., 2006). Similarly,
TGF-β1, secreted by many types of cancer cells, reduces NKG2D
surface expression, impairing tumor cytotoxic recognition by
effector cells (Castriconi et al., 2003). Finally, cytokines such as
IL-12 and IFN-β are associatedwith a reduction of NKG2Dexpres-
sion triggered by interaction with HCMV-infected dendritic cells
(Muntasell et al., 2010).
TWO FAMILIES OF NKG2D-LIGANDS BASED
ON GENE LOCATION
Two families of ligands for the human NKG2D receptor have
been described (Figure 1): the MICA/B encoded in the MHC
region (Bahram et al., 1994; Bauer et al., 1999) and a second fam-
ily of MHC class I-related proteins, the ULBPs, also known as
retinoic acid early transcripts (RAETs), discovered while looking
for ligands of theHCMVglycoproteinUL16 (Cosman et al., 2001),
FIGURE 1 |The two genetic families of ligands for NKG2D. NKG2D-ligands
belong to two genetic families present in different arms of chromosome 6,
giving rise to a large number of proteins with different biochemical properties.
MICA/B are highly polymorphic genes while ULBPs only have a small number
of variants due to single nucleotide polymorphisms. *Number of transcripts
annotated in the Ensembl database (Release 66 – Feb 2012). For the ULBPs,
family studies to show allelic segregation of these variants have not been
performed.
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althoughonlyULBP1, 2, and 6 bindUL16. ULBPs are also encoded
on chromosome 6, but outside the MHC locus. Like conventional
MHC class I molecules, MICA/B proteins contain α1, α2, and α3
domains, however, they do not associate with β2-microglobulin
and they do not present peptides (Groh et al., 1996). To date six
genes, ULBP1–6, have been identiﬁed as belonging to the ULBP
family. These molecules are 55–60% homologous in their amino-
acid sequences, and are equally distantly related to MICs or MHC
(around 20% sequence similarity Cosman et al., 2001; Chalupny
et al., 2003; Eagle et al., 2009). Functionally, the ULBPs are similar
to MICA/B in that they do not bind β2-microglobulin or present
antigenic peptides (Groh et al., 1996), however, in contrast to MIC
proteins, they lack an α3 domain and many of them attach to the
membrane via a GPI-anchor.
MICA/B are highly polymorphic proteins, indeed more than
70 MICA and 30 MICB sequences have been described to date
(Steven GE Marsh, Anthony Nolan Research Institute, http://hla.
alleles.org/terms.html) and a number of diseases have been
reported to be associated with MIC gene polymorphisms, includ-
ing ankylosing spondylitis, Behçet’s disease, psoriasis, type I
diabetes, and Addison’s disease (Stephens, 2001). The sequence
variation that gives rise to these alleles occurs throughout the
protein, but MICA polymorphism is often classiﬁed into several
groups of alleles according to amicrosatellite polymorphism in the
TM region. Strikingly, one of these groups, known as MICA5.1, is
highly frequent in multiple human populations worldwide. MICA
5.1 alleles (for example, MICA*008) contain a frame-shift muta-
tion before the TM region that leads to an early stop codon (Ota
et al., 1997). A number of single nucleotide polymorphisms in
both promoter regions and coding sequences of the RAET1/ULBP
genes has been described (Antoun et al., 2010), although the num-
ber of variant transcripts generated by these mutations is limited
(Figure 1). The signiﬁcance of polymorphism for receptor binding
is unclear since NKG2D is known to bind to its ligands by adapt-
ing the homodimer to the α1/α2 helices of the monomeric ligand
(Strong and McFarland, 2004). The interface between the receptor
and its distinct ligands are stabilized by hydrophobic interac-
tions and hydrogen bonds and, interestingly, different residues
are involved in the interaction with the different ligands in both
human (Li et al., 2001; McFarland et al., 2003) and murine systems
(Wolan et al., 2001). This plasticity in the NKG2D/NKG2D-ligand
interaction allows the receptor to recognize a large number of
diverse molecules in the absence of an important conformational
modiﬁcationupon ligandbinding (Radaev et al., 2001). In the con-
text of MICApolymorphism, it is striking to note that even though
some allelic amino-acid changes are quite dramatic (Pro/His) and
some polymorphic residues lie very close to the NKG2D contact
site, only one dimorphic variant of MIC has been shown to affect
the afﬁnity with which MICA binds to NKG2D and this is a con-
servative substitution, Met or Val at residue 129 (Steinle et al.,
2001). Strikingly, while NKG2D recognizes all its ligands with
sufﬁcient afﬁnity to signal NK cell activation, a number of viral
immune evasion proteins do discriminate between members of
the ULBP and MIC families, binding either MICA or MICB and
some, but not all, of the ULBPs. These observations are con-
sistent with our hypothesis that the biochemical similarities and
differences among NKG2D-ligands can be functionally important
and that these characteristics are independent of the genetic family
to which the NKG2D-ligands pertain.
EXPRESSION OF NKG2D-LIGANDS
Although mRNA for both MICA/B and ULBP proteins can be
found in some normal cells (Cosman et al., 2001; Schrambach
et al., 2007), there is general consensus that the levels of NKG2D-
ligand expression at the cell surface of the vast majority of healthy
cells, are either null or low and clearly below that needed to
activate immune cells expressing NKG2D receptors. Instead, the
expression of these molecules is upregulated when the cells suffer
different types of stress, notably tumoral transformation, viral and
bacterial infection, and in autoimmune diseases. A large variety
of primary tumors and tumor-derived cell lines express NKG2D-
ligands and in the last few years, numerous comprehensive reviews
have been published on the involvement of NKG2D-ligands in
cancer (Nausch and Cerwenka, 2008). Thus, only some aspects
of the complexity of this topic are discussed here. The molecu-
lar mechanisms involved in the regulation of expression of these
molecules upon stress are not clear, however it has been reported
that heat shock, oxidative stress, DNA damage, proteasome inhi-
bition, and histone deacetylases lead to an increased expression
of NKG2D-ligands at the cell surface (for review, see Mistry and
O’Callaghan, 2007; Gonzalez et al., 2008 and references therein).
Of particular interest is that the effect of all those stress stim-
uli leads to differential expression of the various NKG2D-ligands,
depending on the cellular type and/or its metabolic status. For
example, proteasome inhibition speciﬁcally upregulated ULBP2
in Jurkat cells (Vales-Gomez et al., 2008), but ULBP1 in head
and neck squamous cell carcinoma (HNSCC) cells (Butler et al.,
2009). What seems clear is that, in the context of stress, NKG2D-
ligand expression and release are regulated at many cellular levels
including transcriptional, post-transcriptional [mRNA stability
and micro-RNAs (mi-RNAs) Stern-Ginossar et al., 2008; Heine-
mann et al., 2012], and post-translational (protein modiﬁcations,
trafﬁcking, and shedding). As mentioned above, cytokines also
affect the expression of NKG2D-ligands: while IFN-γ downregu-
lates MICA and ULBP2 (Schwinn et al., 2009; Yadav et al., 2009),
IFN-α upregulates its expression (Jinushi et al., 2003; Zhang et al.,
2008). Another level of complexity is that expression of a particu-
lar ligand in different types of cancer can be associated with better
or worse prognosis (Wu et al., 2004; Li et al., 2009; McGilvray et al.,
2009, 2010; Paschen et al., 2009; Nuckel et al., 2010). It thus seems
plausible to suggest that the diversity of NKG2D-ligands detected
in different tumors reﬂects, on one hand, the complexity in the
regulation of their expression at the cellular and tissue microen-
vironment level and, on the other, the contribution from the
biochemical properties conferred by diversity and polymorphism.
Evolution of NKG2D-ligands has been most probably driven by
pathogen pressure, as illustrated by the example of HCMV (see
below), however, the resulting beneﬁt ensuring good recogni-
tion of infected cells can result in differential responses against
tumors, from direct killing of the transformed cell to evasion of
the immune response. Recognition of NKG2D-ligands, either in
soluble form or at the cell surface, can result in downmodulation
anddegradationof the activating receptor (Groh et al.,2001; Roda-
Navarro and Reyburn, 2009) and differences have been observed
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whether the interacting ligand was membrane bound or soluble,
the former beingmore potent for receptor inactivation (Salih et al.,
2002; Coudert et al., 2005).
In the next sections, we will review the cell biology of NKG2D-
ligands and group them according to their biochemical features,
with the idea that this way of thinking may provide useful insights
into the biology of these molecules. All the biochemical features
of NKG2D-ligands discussed in the next sections are summarized
in Table 1.
BIOCHEMICAL FEATURES AND CELL TRAFFICKING
OF NKG2D-LIGANDS
The classiﬁcation of NKG2D-ligands according to their genetic
location correlates with the presence of an α3 domain and with
the primary mode of membrane attachment of these molecules:
MICAandMICBareTMproteinswhereas themost studiedULBPs
(ULBP1–3) are GPI-linked molecules (Figure 1). However, this
classiﬁcation is not so straightforward sinceULBP4 is aTMprotein
(Chalupny et al., 2003; Bacon et al., 2004) and ULBP2 and 5 have
recently been shown to have the potential to be expressed as either
a GPI or a TM protein (Ohashi et al., 2010; Fernandez-Messina
et al., 2011) demonstrating that, depending on cellular context
a single mRNA sequence can encode proteins with two types of
membrane attachment.
Despite these caveats, the observation that murine NKG2D-
ligands are also expressed as either TM or GPI-linked molecules
has led to the suggestion that the conservation of a GPI-anchor in
some, but not all, NKG2D-ligands might be functionally impor-
tant. However, the nature of this putative functional signiﬁcance
remains unclear. In the mouse, GPI-anchored proteins have mod-
est to low afﬁnities for NKG2D, whereas the ligands possessing
TM-cytoplasmic domains have high afﬁnity (O’Callaghan et al.,
2001), but the human NKG2D-ligands do not seem to conform
to this pattern (Strong and McFarland, 2004). Another possibly
relevant difference between GPI-anchored and TM proteins is
that GPI-anchored proteins usually associate with detergent resis-
tant membranes (DRMs), which are regions of the membrane
enriched in sphingolipids and cholesterol. Indeed, the majority of
ULBP1–3 proteins are recruited to these regions of the membrane
(Fernandez-Messina et al., 2010) while only a low proportion of
MICA/B appears in DRMs (Aguera-Gonzalez et al., 2009). How-
ever, this statement does not seem to be a general rule for MICs,
since a high proportion of MICA*008 molecules are also recruited
to DRMs (Ashiru et al., 2010). Clustering of the GPI-anchored
ULBPs within lipid rafts, that are known to polarize to the site
of interaction between the NK cell and the susceptible target cell
(Lou et al., 2000), could increase the avidity of interaction of these
molecules with theNKG2D receptor. In support of this hypothesis,
Martinez et al. (2011) have observed that redistribution of ULBP1
outside of DRM, through the replacement of the GPI linkage in
ULBP1 by the TM region of CD45, resulted in diminished NK
cell responses to target cells expressing these molecules. In con-
trast, a naturally occurring TM form of ULBP2 was as capable of
enhancing NK cell activation as the GPI-linked form of ULBP2
(Fernandez-Messina et al., 2011). Consistent with this observa-
tion, a mutant MICA molecule that could not be recruited to
DRMs triggered NK cell lysis comparably to wild-type MICA
(Aguera-Gonzalez et al., 2011). The reasons for the different results
obtained in these three studies are not clear, but one obvious dif-
ference is that each paper analyzed a different NKG2D-ligand.
It would be interesting to investigate the contribution of these
distinct membrane anchors to the distribution and properties of
speciﬁc ligands on target cells.
Another statement that does not seem to hold true when
NKG2D-ligands are compared, is that possession of a GPI-anchor
leads to a stable linkage to the exoplasmic leaﬂet of the lipid
Table 1 | NKG2D-ligand biochemistry and cell biology.
ULBP1/RAET1I ULBP2/RAET1H ULBP3/RAET1N MICA/long TM –
cytoplasmic tail
MICA/shortTM –
cytoplasmic tail
MICB
Stability at the cell surface1 (hour) <4 >4 >4 >4 >4 <4
DRMs (%) ∼100 ∼100 ∼100 ∼15 ∼70% ∼15%
Maturation2 >2 h >2 h 30 min 30 min NA >2 h
Release
Exosomes Low3 Low4 Y Low4 Y Low
Soluble Low3 ADAM Low ADAM/MMP14 Low ADAM
Viral evasion
HCMV-UL16 (downmodulation) Y Y N N P Y
HCMV-UL142 (downmodulation) N N Y Y N N
HIV-Nef (downmodulation) Y Y NA Y5 Y5 NA
Y, yes; N, no; P, partially; NA, not addressed.
1Time to reach 50% reduction in cell surface expression after blockade of protein synthesis and recycling.
250% of protein mature after the indicated time, as evaluated in pulse-chase experiments.
3In general, present at low levels and in exosomal fractions of certain cells.
4Enhanced by metalloprotease inhibitors.
5The alleles were not speciﬁed in the study.
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bilayer, resistant to proteases and lipases. In fact, it is known that
GPI-anchored proteins can be endocytosed (for review, see Sab-
haranjak and Mayor, 2004; Maeda and Kinoshita, 2011). Indeed,
analysis of the stability of the NKG2D-ligand at the cell surface
reveals important differences in the half-life of these molecules
that do not correlate with the form of membrane anchoring:
MICA and ULBP2, 3 are quite stable at the plasma membrane,
ULBP1 disappears with faster kinetics (Fernández-Messina, 2011)
and MICB has a very short half-life at the plasma membrane
(Aguera-Gonzalez et al., 2009).
RELEASE OF NKG2D-LIGANDS
The presence of soluble NKG2D-ligands in serum from cancer
patients and the persistent engagement of the NKG2D recep-
tor has been related with an impairment of NKG2D-mediated
cytolytic functions (Salih et al., 2008 and references therein).
Thus, the mechanisms underlying NKG2D-ligand release have
been intensively studied in the last few years and, here again,
marked similarities and differences between NKG2D-ligands that
do not correlate with genetic family to which the ligands belong
have been observed. MICA molecules with long TM and cytoso-
lic domains (Salih et al., 2002), MICB (Boutet et al., 2009), and
ULBP2 (Waldhauer and Steinle, 2006) are shed after proteolytic
cleavage mediated by metalloproteases, whereas MICA*008 (short
TM and cytoplasmic tail) and ULBP3 molecules are released
as full-length proteins located in exosomes (Ashiru et al., 2010;
Fernandez-Messina et al., 2010). Much less ULBP1 is released than
either ULBP2 or 3, when comparing supernatants from the same
cellular system. These data support the existence of intrinsic dif-
ferences between the biochemistry of the NKG2D-ligands that do
not correlate with a MIC/ULBP classiﬁcation, and revealed that
the integrity of cellular trafﬁcking can have a marked inﬂuence
on the behavior of the different NKG2D-ligands. Treatment of
cells with metalloprotease inhibitors, led to the recruitment of
ULBP2 into exosomes (Fernandez-Messina et al., 2010). Similarly,
MICA*019, normally shed as a solublemolecule, can also be found
in exosomes after metalloprotease inhibition (Fernández-Messina,
2011). Thus, ULBP2 and MICA*019 could trafﬁc to multivesicu-
lar bodies for incorporation into exosomes, but do not complete
this journey because of cleavage by metalloproteases. In fact, all
the ULBPs were found in exosomes derived from placental tis-
sues (Hedlund et al., 2009) and ULBP1 in dendritic cell-derived
exosomes (Viaud et al., 2009). Membrane compartmentalization
of metalloproteases and NKG2D-ligands may represent one level
of regulation of trafﬁcking and shedding of the NKG2D-ligands
since recruitment of both sheddase and ligand to DRMs was
crucial for efﬁcient proteolytic release of MICB (Boutet et al.,
2009). Moreover, palmitoylation has been shown to regulate the
recruitment of MICA to DRMs and also to markedly inﬂuence
shedding (Aguera-Gonzalez et al., 2011). However, other levels
of post-translational regulation of this process are likely to exist,
for example the thiol-isomerase endoplasmic reticulum protein
(ERp)5, has also been reported to modulate MICA shedding
(Kaiser et al., 2007).
The consequences of all these different mechanisms for
NKG2D-ligand release are not trivial with regard to immune
recognition. It is important to remember here that although
MIC and ULBP molecules can be potent activating ligands for
NKG2D, persistent chronic engagement of NKG2D upon inter-
action with surface ligands leads to receptor downmodulation
and loss of function (Coudert et al., 2005; Oppenheim et al.,
2005; Wiemann et al., 2005). Thus, it is difﬁcult to predict
how the expression of NKG2D-ligands could affect the inten-
sity of an immune response of a cancer patient since this will
depend on multiple factors including the presence of NKG2D-
ligands in serum and, as discussed above, the particular cytokine
milieu that could oppose or enhance NKG2D downmodulation
by serum NKG2D-ligands. Further, the biochemical forms of
NKG2D-ligands found in patients’ sera may vary ﬁrstly, depend-
ing on the particular alleles encoded in that individual’s genome
and, secondly, on the effect that tumor transformation could
have on the cellular pathways needed for the molecule to reach
either the cell surface or the extracellular milieu. So, while the
MICA*008 allele and ULBP3 are generally released in exosomes,
many MICA/B molecules and ULBP2 can be shed as either sol-
uble proteins or in exosomes depending on the metalloprotease
activity in the cell (see above). This distinction is important
since TM proteins at the surface of exosomes are presented in
the same orientation as those at the cell surface (Simons and
Raposo, 2009). In this sense, an exosome can be considered as
a nanoparticle presenting multimeric NKG2D-ligands and it has
been reported that exosomal NKG2D-ligands are more potent
downmodulators of the NKG2D receptor than cleaved, soluble
molecules (Ashiru et al., 2010; Fernandez-Messina et al., 2010).
It is important to note that although MICA*008 can be released
as a full-length protein in exosomes, this does not imply that it
cannot be detected in patients sera since the method for detec-
tion does not distinguish between these two biochemical forms.
Indeed, soluble MICA molecules can be detected in patients’
sera regardless of presumed allelic MICA differences, and in
particular high sMICA levels have been found in MICA 5.1+
individuals (i.e., mostly MICA*008; Hue et al., 2004). Thus, the
expression of NKG2D-ligands could modulate in many differ-
ent manners the intensity of the immune response of a cancer
patient. Each one of these possibilities has different outcomes
for the immune system and, identiﬁcation of the particular
route used to release NKG2D-ligands could provide information
on immune system integrity and/or cellular routes affected in
the tumor.
NKG2D-LIGANDS, CELL BIOLOGY, AND PATHOGEN
IMMUNE EVASION STRATEGIES
The release of NKG2D-ligands from cells discussed above is
thought to be a major mechanism for tumor cell evasion of
NKG2D-mediated immune surveillance. However, apart from
cancer, theNKG2D systemplays a role in several other pathological
situations that involve some degree of cellular stress, includ-
ing transplantation (Collins, 2004; Suarez-Alvarez et al., 2006),
autoimmune diseases (Van Belle and von Herrath, 2009), and
pathogen infection (Borchers et al., 2006). The observation that
a number of pathogens, especially viruses, have developed strate-
gies to evade NKG2D-mediated recognition shows the importance
of this system to control infection. Immunoevasin discrimina-
tion between NKG2D-ligands presumably reﬂects the existence
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of important functional differences between the NKG2D-ligands.
For example, the HCMV glycoprotein UL16 blocks surface expres-
sion of ULBP1, 2, 6, and MICB, but not MICA, ULBP3, or
ULBP4/RAET1E (Chalupny et al., 2003; Dunn et al., 2003; Rolle
et al., 2003; Vales-Gomez et al., 2003; Welte et al., 2003). How-
ever, the HCMV-UL142 protein downmodulates MICA and
ULBP3, but does not affect the alleles of MICA with a short
TM/cytoplasmic tail or ULBP2 (Chalupny et al., 2006; Ashiru
et al., 2009; Bennett et al., 2010). Consideration of several aspects
of NKG2D-ligand cell biology (Table 1) can provide a novel
perspective that may prove useful in understanding the inter-
action of immunoevasins with speciﬁc NKG2D-ligands as well
as providing insights into the mechanisms of action of these
molecules. For example, the rate of maturation of NKG2D-
ligands varies among the individual molecules, ranging from
30 min to more than 2 h for ER exit, implying that each
NKG2D-ligand follows different cellular routes and/or suffers
different post-translational modiﬁcations. Interestingly, in some
cases this biological variability can be correlated with the interac-
tion of NKG2D-ligands with viral immunoevasins: for example,
HCMV-UL142 preferentially binds those proteins that leave the
ER rapidly, while HCMV-UL16 efﬁciently sequesters those that
share the property of slow exit from the ER. It is striking to
note that UL16 also leaves the ER only very slowly (Vales-Gomez
et al., 2006), paralleling the behavior of the NKG2D-ligands with
which it interacts, perhaps implying that this shared trafﬁck-
ing property is important for the intracellular accumulation of
NKG2D-ligands mediated by UL16. The selective binding of
UL16 to speciﬁc NKG2D-ligands may also be inﬂuenced by the
strength of the interaction between the luminal domains of the
viral protein and the NKG2D-ligand (Muller et al., 2010) and it
seems reasonable to propose that viruses speciﬁcally target lig-
ands according to features such as binding and/or trafﬁcking.
A number of other viruses also target speciﬁc NKG2D-ligands
including human herpesvirus-7 (HHV-7; Schneider and Hud-
son, 2011) that redirects ULBP1 molecules to lysosomes, and
the Kaposi’s sarcoma-associated herpesvirus K5 protein that pro-
motes degradation of MICA molecules upon ubiquitylation of
a lysine motif in the cytoplasmic tail (Thomas et al., 2008).
Interestingly, both the GPI-anchored NKG2D-ligand proteins
and the short-tailed alleles of MICA, lacking cytoplasmic tail,
are resistant to degradation by this latter mechanism. The
HHV-7 U21 gene also downmodulates MICA and MICB at
a post-translational step, although the mechanism underlying
this phenomenon is not completely understood. In contrast,
those immune evasion proteins that downmodulate multiple
NKG2D-ligands, for example, HIV-Nef that acts on all the
NKG2D-ligands tested (ULBP1, 2, and MICA; Cerboni et al.,
2007), seem likely to target some feature highly conserved
between the different NKG2D-ligands. Thus, the existence of
viral immunoevasins that selectively target some, but not all,
NKG2D-ligands clearly demonstrates the existence of impor-
tant differences in the biochemistry and cell biology of these
molecules. Moreover identiﬁcation of functionally important
features that correlate with susceptibility to recognition by an
immunoevasin may be a useful approach to shed light on its
mechanism of action.
An additional level of viral regulation of ligand expression
is represented by mi-RNAs: diverse herpes and polyomaviruses
encode mi-RNAs that target NKG2D-ligand mRNA, to reduce
their expression (Nachmani et al., 2009). However, here again, it
is possible to argue that biochemical differences between the dif-
ferent NKG2D-ligands may have inﬂuenced the evolution of the
speciﬁcity of these mi-RNAs. For example the HCMV mi-RNA
UL112 acts to reduce expression of MICB, but not MICA. It is
tempting to speculate that it is advantageous for the virus to have
evolved a mi-RNA able to speciﬁcally block MICB transcription
because the short half-life of MICB at the cell surface would mean
a rapid loss of surface protein after blockade of mRNA transcrip-
tion (Aguera-Gonzalez et al., 2009). In contrast, the action of a
viral protein would be required to actively sequester the much
more stably expressed MICA protein.
CONCLUDING REMARKS
Review of the biochemical properties of the different NKG2D-
ligands supports the idea that evolution of these molecules was
signiﬁcantly driven as a result of selective pressure exerted by
a range of stress signals and pathogen infections: if an insult
resulted in blockade of a particular cellular pathway, obstructing
the expression of an NKG2D-ligand, the existence of a differ-
ent ligand that could follow an alternative route to make the cell
visible to the immune system would be an advantage. If, how-
ever, the actual set of ligands for the NKG2D receptor was the
result of a process of evolution for diversity, it is not surprising
that the biochemical properties of a given NKG2D-ligand do not
necessarily reﬂect the behavior of other members of its genetic
family. This kind of consideration reinforces the necessity for
further studies to analyze the cell biology and biochemistry of
the individual NKG2D-ligands in detail. This information will
be especially important for understanding the role of this sys-
tem in disease, in particular the detection of speciﬁc soluble
NKG2D-ligands in the sera of patients suffering cancer. Although
in many cases correlations between the levels of soluble lig-
ands and disease progression have been reported, it is reasonable
to suggest that identifying the NKG2D-ligand genotype of the
patient, in particular long versus short MICA molecules, can
contribute to their use as biomarkers. In this sense, it might
well be worthwhile to revisit previous reports looking at which
particular NKG2D-ligand was studied, not whether it was a
MIC or a ULBP. Given that aberrant expression of NKG2D-
ligands is involved in the pathogenesis of both cancer and various
autoimmune diseases, learning the lessons of NKG2D-ligand cell
biology may represent a useful approach to develop novel strate-
gies to permit selective or general manipulation of this system in
disease.
ACKNOWLEDGMENTS
Work in the authors’ laboratories are supported by grants from the
Spanish Fondode Investigación Sanitaria (PS09/00181, PI08/1701,
and PI11/00298). Lola Fernández-Messina is supported by the
Comunidad de Madrid (grant S2010/BMD-2326 to Mar Valés-
Gómez). We would like to thank Dr. P. Roda-Navarro for critically
reading the manuscript.
Frontiers in Immunology | NK Cell Biology September 2012 | Volume 3 | Article 299 | 6
“ﬁmmu-03-00299” — 2012/9/24 — 10:40 — page 7 — #7
Fernández-Messina et al. Cell biology of NKG2D-ligands
REFERENCES
Aguera-Gonzalez, S., Boutet, P., Rey-
burn, H. T., and Vales-Gomez,
M. (2009). Brief residence at the
plasma membrane of the MHC
class I-related chain B is due
to clathrin-mediated cholesterol-
dependent endocytosis and shedding.
J. Immunol. 182, 4800–4808.
Aguera-Gonzalez, S., Gross, C. C.,
Fernandez-Messina, L., Ashiru, O.,
Esteso, G., Hang, H. C., Rey-
burn, H. T., Long, E. O., and
Vales-Gomez, M. (2011). Palmitoyla-
tion of MICA, a ligand for NKG2D,
mediates its recruitment to mem-
brane microdomains and promotes
its shedding. Eur. J. Immunol. 41,
3667–3676.
Allez, M., Tieng, V., Nakazawa, A.,
Treton, X., Pacault, V., Dulphy, N.,
Caillat-Zucman, S., Paul, P., Gor-
net, J. M., Douay, C., Ravet, S.,
Tamouza, R., Charron, D., Lemann,
M., Mayer, L., and Toubert, A.
(2007). CD4+NKG2D+ T cells in
Crohn’s disease mediate inﬂamma-
tory and cytotoxic responses through
MICA interactions. Gastroenterology
132, 2346–2358.
Antoun, A., Jobson, S., Cook, M.,
O’Callaghan, C. A., Moss, P.,
and Briggs, D. C. (2010). Sin-
gle nucleotide polymorphism anal-
ysis of the NKG2D ligand cluster
on the long arm of chromosome 6:
extensive polymorphisms and evi-
dence of diversity between human
populations. Hum. Immunol. 71,
610–620.
Ashiru, O., Bennett, N. J., Boyle, L. H.,
Thomas, M., Trowsdale, J., and Wills,
M. R. (2009). NKG2D ligand MICA
is retained in the cis-Golgi apparatus
by human cytomegalovirus protein
UL142. J. Virol. 83, 12345–12354.
Ashiru, O., Boutet, P., Fernandez-
Messina, L., Aguera-Gonzalez, S.,
Skepper, J. N., Vales-Gomez, M.,
and Reyburn, H. T. (2010). Natural
killer cell cytotoxicity is suppressed by
exposure to the human NKG2D lig-
and MICA*008 that is shed by tumor
cells in exosomes. Cancer Res. 70,
481–489.
Bacon, L., Eagle, R. A., Meyer,
M., Easom, N., Young, N. T.,
and Trowsdale, J. (2004). Two
humanULBP/RAET1moleculeswith
transmembrane regions are ligands
for NKG2D. J. Immunol. 173,
1078–1084.
Bahram, S., Bresnahan, M., Geraghty,
D. E., and Spies, T. (1994). A second
lineage of mammalian major histo-
compatibility complex class I genes.
Proc. Natl. Acad. Sci. U.S.A. 91,
6259–6263.
Bauer, S., Groh, V., Wu, J., Steinle,
A., Phillips, J. H., Lanier, L. L., and
Spies, T. (1999). Activation of NK
cells and T cells by NKG2D, a recep-
tor for stress-inducibleMICA.Science
285, 727–729.
Bennett, N. J., Ashiru, O., Morgan, F.
J., Pang, Y., Okecha, G., Eagle, R. A.,
Trowsdale, J., Sissons, J. G., and Wills,
M. R. (2010). Intracellular sequestra-
tion of the NKG2D ligand ULBP3 by
human cytomegalovirus. J. Immunol.
185, 1093–1102.
Borchers, M. T., Harris, N. L., Wes-
selkamper, S. C., Zhang, S., Chen, Y.,
Young, L., and Lau, G.W. (2006). The
NKG2D-activating receptor mediates
pulmonary clearance of Pseudomonas
aeruginosa. Infect. Immun. 74,
2578–2586.
Boutet, P., Aguera-Gonzalez, S., Atkin-
son, S., Pennington, C. J., Edwards,
D. R., Murphy, G., Reyburn, H.
T., and Vales-Gomez, M. (2009).
Cutting edge: the metalloproteinase
ADAM17/TNF-alpha-converting en-
zyme regulates proteolytic shed-
ding of the MHC class I-related
chain B protein. J. Immunol. 182,
49–53.
Brown, M. G., Fulmek, S., Matsumoto,
K., Cho, R., Lyons, P. A., Levy, E.
R., Scalzo, A. A., and Yokoyama, W.
M. (1997). A 2-Mb YAC contig and
physicalmapof thenatural killer gene
complex on mouse chromosome 6.
Genomics 42, 16–25.
Burgess, S. J., Marusina, A. I., Path-
manathan, I., Borrego, F., and
Coligan, J. E. (2006). IL-21 down-
regulates NKG2D/DAP10 expression
on human NK and CD8+ T cells. J.
Immunol. 176, 1490–1497.
Butler, J. E., Moore, M. B., Presnell,
S. R., Chan, H. W., Chalupny, N. J.,
and Lutz, C. T. (2009). Proteasome
regulation of ULBP1 transcription. J.
Immunol. 182, 6600–6609.
Capraru, D., Muller, A., Csernok, E.,
Gross, W. L., Holl-Ulrich, K., North-
ﬁeld, J., Klenerman, P., Herlyn, K.,
Holle, J., Gottschlich, S., Voswinkel,
J., Spies, T., Fagin, U., Jabs, W. J.,
and Lamprecht, P. (2008). Expan-
sion of circulating NKG2D+ effector
memory T-cells and expression of
NKG2D-ligand MIC in granulomao-
us lesions in Wegener’s granu-
lomatosis. Clin. Immunol. 127,
144–150.
Castriconi, R., Cantoni, C., Della
Chiesa, M., Vitale, M., Marcenaro, E.,
Conte, R., Biassoni, R., Bottino, C.,
Moretta, L., and Moretta, A. (2003).
Transforming growth factor beta 1
inhibits expression of NKp30 and
NKG2D receptors: consequences for
the NK-mediated killing of dendritic
cells. Proc. Natl. Acad. Sci. U.S.A. 100,
4120–4125.
Cerboni, C., Neri, F., Casartelli, N.,
Zingoni, A., Cosman, D., Rossi,
P., Santoni, A., and Doria, M.
(2007). Human immunodeﬁciency
virus 1 Nef protein downmodulates
the ligands of the activating recep-
torNKG2Dand inhibits natural killer
cell-mediated cytotoxicity. J. Gen.
Virol. 88, 242–250.
Collins, R. W. (2004). Human MHC
class I chain related (MIC) genes:
their biological function and rel-
evance to disease and transplan-
tation. Eur. J. Immunogenet. 31,
105–114.
Cosman, D., Mullberg, J., Suther-
land, C. L., Chin, W., Armitage,
R., Fanslow, W., Kubin, M., and
Chalupny, N. J. (2001). ULBPs,
novel MHC class I-related molecules,
bind to CMV glycoprotein UL16 and
stimulate NK cytotoxicity through
the NKG2D receptor. Immunity 14,
123–133.
Coudert, J. D., Zimmer, J., Tomasello,
E., Cebecauer, M., Colonna, M.,
Vivier, E., and Held, W. (2005).
Altered NKG2D function in NK
cells induced by chronic exposure
to NKG2D ligand-expressing tumor
cells. Blood 106, 1711–1717.
Chalupny, N. J., Rein-Weston, A.,
Dosch, S., and Cosman, D.
(2006). Down-regulation of the
NKG2D ligand MICA by the
human cytomegalovirus glyco-
protein UL142. Biochem. Biophys.
Res. Commun. 346, 175–181.
Chalupny, N. J., Sutherland, C. L.,
Lawrence, W. A., Rein-Weston, A.,
and Cosman, D. (2003). ULBP4 is
a novel ligand for human NKG2D.
Biochem. Biophys. Res. Commun. 305,
129–135.
Champsaur, M., and Lanier, L.
L. (2010). Effect of NKG2D lig-
and expression on host immune
responses. Immunol. Rev. 235,
267–285.
Chan, C. W., Crafton, E., Fan, H.
N., Flook, J., Yoshimura, K., Skar-
ica, M., Brockstedt, D., Dubensky, T.
W., Stins, M. F., Lanier, L. L., Par-
doll, D. M., and Housseau, F. (2006).
Interferon-producing killer dendritic
cells provide a link between innate
and adaptive immunity. Nat. Med. 12,
207–213.
Dann, S. M., Wang, H. C., Gambarin,
K. J., Actor, J. K., Robinson, P.,
Lewis, D. E., Caillat-Zucman, S., and
White, A. C. Jr. (2005). Interleukin-
15 activates human natural killer
cells to clear the intestinal protozoan
cryptosporidium. J. Infect. Dis. 192,
1294–1302.
Dhanji, S., and Teh, H. S. (2003).
IL-2-activated CD8+CD44high
cells express both adaptive and
innate immune system receptors
and demonstrate speciﬁcity for syn-
geneic tumor cells. J. Immunol. 171,
3442–3450.
Dunn, C., Chalupny, N. J., Suther-
land, C. L., Dosch, S., Sivakumar,
P. V., Johnson, D. C., and Cosman,
D. (2003). Human cytomegalovirus
glycoprotein UL16 causes intracel-
lular sequestration of NKG2D lig-
ands, protecting against natural killer
cell cytotoxicity. J. Exp. Med. 197,
1427–1439.
Eagle, R. A., Traherne, J. A., Hair,
J. R., Jafferji, I., and Trowsdale, J.
(2009). ULBP6/RAET1L is an addi-
tional human NKG2D ligand. Eur. J.
Immunol. 39, 3207–3216.
Eagle, R. A., and Trowsdale, J. (2007).
Promiscuity and the single recep-
tor: NKG2D. Nat. Rev. Immunol. 7,
737–744.
Ebert, E. C. (2005). IL-15 converts
human intestinal intraepithelial
lymphocytes to CD94 producers of
IFN-gamma and IL-10, the latter
promoting Fas ligand-mediated
cytotoxicity. Immunology 115,
118–126.
Fernández-Messina, L. (2011). Studies
on the biochemistry and cell biology
of the glycosyl-phosphatidylinositol
(GPI)-anchored NKG2D-ligands.
PhD thesis, University of Cambridge,
Cambridge.
Fernandez-Messina, L., Ashiru, O.,
Aguera-Gonzalez, S., Reyburn, H. T.,
and Vales-Gomez, M. (2011). The
human NKG2D ligand ULBP2 can be
expressed at the cell surface with or
without aGPI anchor and both forms
can activate NK cells. J. Cell Sci. 124,
321–327.
Fernandez-Messina, L., Ashiru, O.,
Boutet, P.,Aguera-Gonzalez, S., Skep-
per, J. N., Reyburn, H. T., and
Vales-Gomez, M. (2010). Differen-
tial mechanisms of shedding of the
glycosylphosphatidylinositol (GPI)-
anchored NKG2D ligands. J. Biol.
Chem. 285, 8543–8551.
Gilﬁllan, S., Ho, E. L., Cella, M.,
Yokoyama, W. M., and Colonna, M.
(2002). NKG2D recruits two distinct
adapters to trigger NK cell activation
and costimulation. Nat. Immunol. 3,
1150–1155.
Gonzalez, S., Lopez-Soto, A., Suarez-
Alvarez, B., Lopez-Vazquez, A., and
Lopez-Larrea, C. (2008). NKG2D lig-
ands: key targets of the immune
response. Trends Immunol. 29,
397–403.
Groh, V., Bahram, S., Bauer, S.,
Herman, A., Beauchamp, M.,
www.frontiersin.org September 2012 | Volume 3 | Article 299 | 7
“ﬁmmu-03-00299” — 2012/9/24 — 10:40 — page 8 — #8
Fernández-Messina et al. Cell biology of NKG2D-ligands
and Spies, T. (1996). Cell stress-
regulated human major histocom-
patibility complex class I gene
expressed in gastrointestinal epithe-
lium. Proc. Natl. Acad. Sci. U.S.A. 93,
12445–12450.
Groh, V., Bruhl, A., El-Gabalawy, H.,
Nelson, J. L., and Spies, T. (2003).
Stimulation of T cell autoreactivity
by anomalous expression of NKG2D
and its MIC ligands in rheumatoid
arthritis. Proc. Natl. Acad. Sci. U.S.A.
100, 9452–9457.
Groh, V., Rhinehart, R., Randolph-
Habecker, J., Topp, M. S., Riddell,
S. R., and Spies, T. (2001). Cos-
timulation of CD8alphabeta T cells
by NKG2D via engagement by MIC
induced on virus-infected cells. Nat.
Immunol. 2, 255–260.
Groh, V., Smythe, K., Dai, Z., and
Spies, T. (2006). Fas-ligand-mediated
paracrine T cell regulation by the
receptorNKG2D in tumor immunity.
Nat. Immunol. 7, 755–762.
Hedlund, M., Stenqvist, A. C., Nagaeva,
O., Kjellberg, L., Wulff, M., Bara-
nov, V., and Mincheva-Nilsson, L.
(2009). Human placenta expresses
and secretes NKG2D ligands via exo-
somes that down-modulate the cog-
nate receptor expression: evidence
for immunosuppressive function. J.
Immunol. 183, 340–351.
Heinemann, A., Zhao, F., Pechli-
vanis, S., Eberle, J., Steinle, A.,
Diederichs, S., Schadendorf, D., and
Paschen, A. (2012). Tumor suppres-
sive microRNAs miR-34a/c control
cancer cell expression of ULBP2, a
stress-induced ligand of the natural
killer cell receptor NKG2D. Cancer
Res. 72, 460–471.
Houchins, J. P., Yabe, T., Mcsherry,
C., and Bach, F. H. (1991). DNA
sequence analysis of NKG2, a fam-
ily of related cDNA clones encoding
type II integral membrane proteins
on human natural killer cells. J. Exp.
Med. 173, 1017–1020.
Hue, S., Mention, J. J., Monteiro, R.
C., Zhang, S., Cellier, C., Schmitz,
J., Verkarre, V., Fodil, N., Bahram,
S., Cerf-Bensussan, N., and Caillat-
Zucman, S. (2004). A direct role
for NKG2D/MICA interaction in vil-
lous atrophy during celiac disease.
Immunity 21, 367–377.
Jamieson,A.M.,Diefenbach,A.,Mcma-
hon, C. W., Xiong, N., Carlyle, J. R.,
and Raulet, D. H. (2002). The role
of the NKG2D immunoreceptor in
immune cell activation and natural
killing. Immunity 17, 19–29.
Jinushi, M., Takehara, T., Kanto, T., Tat-
sumi, T., Groh, V., Spies, T., Miyagi,
T., Suzuki, T., Sasaki, Y., and Hayashi,
N. (2003). Critical role of MHC class
I-related chain A and B expression on
IFN-alpha-stimulated dendritic cells
in NK cell activation: impairment in
chronic hepatitis C virus infection. J.
Immunol. 170, 1249–1256.
Kaiser, B. K., Yim, D., Chow, I. T., Gon-
zalez, S., Dai, Z.,Mann,H.H., Strong,
R. K., Groh, V., and Spies, T. (2007).
Disulphide-isomerase-enabled shed-
ding of tumour-associated NKG2D
ligands. Nature 447, 482–486.
Li, K., Mandai, M., Hamanishi, J.,
Matsumura, N., Suzuki, A., Yagi,
H., Yamaguchi, K., Baba, T., Fujii,
S., and Konishi, I. (2009). Clinical
signiﬁcance of the NKG2D ligands,
MICA/B and ULBP2 in ovarian can-
cer: high expression of ULBP2 is an
indicator of poor prognosis. Cancer
Immunol. Immunother. 58, 641–652.
Li, P., Morris, D. L., Willcox, B. E.,
Steinle, A., Spies, T., and Strong, R.
K. (2001). Complex structure of the
activating immunoreceptor NKG2D
and its MHC class I-like ligand
MICA. Nat. Immunol. 2, 443–451.
Lou, Z., Jevremovic, D., Billadeau,D. D.,
and Leibson, P. J. (2000). A balance
between positive and negative signals
in cytotoxic lymphocytes regulates
the polarization of lipid rafts dur-
ing the development of cell-mediated
killing. J. Exp. Med. 191, 347–354.
Maasho, K., Opoku-Anane, J.,
Marusina, A. I., Coligan, J. E.,
and Borrego, F. (2005). NKG2D is
a costimulatory receptor for human
naive CD8+ T cells. J. Immunol. 174,
4480–4484.
Maeda, Y., and Kinoshita, T. (2011).
Structural remodeling, trafﬁcking
and functions of glycosylphos-
phatidylinositol-anchored proteins.
Prog. Lipid Res. 50, 411–424.
Martinez, E., Brzostowski, J. A., Long, E.
O., and Gross, C. C. (2011). Cutting
edge: NKG2D-dependent cytotoxic-
ity is controlled by ligand distribu-
tion in the target cell membrane. J.
Immunol. 186, 5538–5542.
McFarland, B. J., Kortemme, T.,Yu, S. F.,
Baker, D., and Strong, R. K. (2003).
Symmetry recognizing asymmetry:
analysis of the interactions between
the C-type lectin-like immunorecep-
tor NKG2D and MHC class I-like
ligands. Structure 11, 411–422.
McGilvray, R. W., Eagle, R. A., Rol-
land, P., Jafferji, I., Trowsdale, J., and
Durrant, L. G. (2010). ULBP2 and
RAET1E NKG2D ligands are inde-
pendent predictors of poor prognosis
in ovarian cancer patients. Int. J.
Cancer 127, 1412–1420.
McGilvray, R. W., Eagle, R. A., Watson,
N. F., Al-Attar, A., Ball, G., Jafferji,
I., Trowsdale, J., and Durrant, L. G.
(2009). NKG2D ligand expression in
human colorectal cancer reveals asso-
ciations with prognosis and evidence
for immunoediting. Clin. Cancer Res.
15, 6993–7002.
Meresse, B., Chen, Z., Ciszewski, C.,
Tretiakova, M., Bhagat, G., Krausz,
T. N., Raulet, D. H., Lanier, L. L.,
Groh, V., Spies, T., Ebert, E. C.,
Green, P. H., and Jabri, B. (2004).
Coordinated induction by IL15
of a TCR-independent NKG2D
signaling pathway converts CTL
into lymphokine-activated killer cells
in celiac disease. Immunity 21,
357–366.
Mistry, A. R., and O’Callaghan, C.
A. (2007). Regulation of ligands
for the activating receptor NKG2D.
Immunology 121, 439–447.
Muller, S., Zocher, G., Steinle, A.,
and Stehle, T. (2010). Structure of
the HCMV UL16-MICB complex
elucidates select binding of a viral
immunoevasin to diverse NKG2D
ligands. PLoS Pathog. 6, e1000723.
doi: 10.1371/journal.ppat.1000723
Muntasell, A., Magri, G., Pende,
D., Angulo, A., and Lopez-Botet,
M. (2010). Inhibition of NKG2D
expression in NK cells by cytokines
secreted in response to human
cytomegalovirus infection. Blood
115, 5170–5179.
Nachmani, D., Stern-Ginossar, N.,
Sarid, R., and Mandelboim, O.
(2009). Diverse herpesvirus microR-
NAs target the stress-induced
immune ligand MICB to escape
recognition by natural killer cells.
Cell Host Microbe 5, 376–385.
Nausch, N., and Cerwenka, A. (2008).
NKG2D ligands in tumor immunity.
Oncogene 27, 5944–5958.
Nuckel, H., Switala, M., Sellmann, L.,
Horn, P. A., Durig, J., Duhrsen,
U., Kuppers, R., Grosse-Wilde,
H., and Rebmann, V. (2010). The
prognostic signiﬁcance of soluble
NKG2D ligands in B-cell chronic
lymphocytic leukemia. Leukemia 24,
1152–1159.
O’Callaghan, C. A., Cerwenka, A., Will-
cox, B. E., Lanier, L. L., and Bjork-
man, P. J. (2001). Molecular com-
petition for NKG2D: H60 and RAE1
compete unequally for NKG2D with
dominance of H60. Immunity 15,
201–211.
Ohashi, M., Eagle, R. A., and Trowsdale,
J. (2010). Post-translational modiﬁ-
cation of theNKG2D ligandRAET1G
leads to cell surface expression
of a glycosylphosphatidylinositol-
linked isoform. J. Biol. Chem. 285,
16408–16415.
Oppenheim, D. E., Roberts, S. J.,
Clarke, S. L., Filler, R., Lewis,
J. M., Tigelaar, R. E., Girardi,
M., and Hayday, A. C. (2005).
Sustained localized expression of lig-
and for the activating NKG2D recep-
tor impairs natural cytotoxicity in
vivo and reduces tumor immuno-
surveillance. Nat. Immunol. 6,
928–937.
Ota, M., Katsuyama, Y., Mizuki, N.,
Ando, H., Furihata, K., Ono, S.,
Pivetti-Pezzi, P., Tabbara, K. F., Pal-
imeris, G. D., Nikbin, B., Davatchi,
F., Chams, H., Geng, Z., Bahram,
S., and Inoko, H. (1997). Trinu-
cleotide repeat polymorphism within
exon 5 of the MICA gene (MHC class
I chain-related gene A): allele fre-
quency data in the nine population
groups Japanese, Northern Han, Hui,
Uygur, Kazakhstan, Iranian, Saudi
Arabian, Greek and Italian. Tissue
Antigens 49, 448–454.
Paschen, A., Sucker, A., Hill, B., Moll, I.,
Zapatka, M., Nguyen, X. D., Sim, G.
C., Gutmann, I., Hassel, J., Becker, J.
C., Steinle, A., Schadendorf, D., and
Ugurel, S. (2009). Differential clinical
signiﬁcanceof individualNKG2D lig-
ands in melanoma: soluble ULBP2 as
an indicator of poor prognosis supe-
rior to S100B. Clin. Cancer Res. 15,
5208–5215.
Radaev, S., Rostro, B., Brooks, A. G.,
Colonna, M., and Sun, P. D. (2001).
Conformational plasticity revealedby
the cocrystal structure of NKG2Dand
its class I MHC-like ligand ULBP3.
Immunity 15, 1039–1049.
Raulet, D. H. (2003). Roles of the
NKG2D immunoreceptor and its lig-
ands. Nat. Rev. Immunol. 3, 781–790.
Roda-Navarro, P., and Reyburn, H.
T. (2009). The trafﬁc of the
NKG2D/Dap10 receptor complex
during natural killer (NK) cell acti-
vation. J. Biol. Chem. 284, 16463–
16472.
Rolle, A., Mousavi-Jazi, M., Eriks-
son, M., Odeberg, J., Soderberg-
Naucler, C., Cosman, D., Karre, K.,
and Cerboni, C. (2003). Effects of
human cytomegalovirus infection on
ligands for the activating NKG2D
receptor of NK cells: up-regulation
of UL16-binding protein (ULBP)1
and ULBP2 is counteracted by the
viral UL16 protein. J. Immunol. 171,
902–908.
Sabharanjak, S., and Mayor, S. (2004).
Folate receptor endocytosis and traf-
ﬁcking. Adv. Drug Deliv. Rev. 56,
1099–1109.
Saez-Borderias, A., Guma, M., Angulo,
A., Bellosillo, B., Pende, D., and
Lopez-Botet, M. (2006). Expres-
sion and function of NKG2D in
CD4+ T cells speciﬁc for human
cytomegalovirus. Eur. J. Immunol. 36,
3198–3206.
Frontiers in Immunology | NK Cell Biology September 2012 | Volume 3 | Article 299 | 8
“ﬁmmu-03-00299” — 2012/9/24 — 10:40 — page 9 — #9
Fernández-Messina et al. Cell biology of NKG2D-ligands
Salih, H. R., Holdenrieder, S., and
Steinle, A. (2008). Soluble NKG2D
ligands: prevalence, release, and func-
tional impact. Front. Biosci. 13,
3448–3456.
Salih, H. R., Rammensee, H. G., and
Steinle, A. (2002). Cutting edge:
down-regulation of MICA on human
tumors by proteolytic shedding. J.
Immunol. 169, 4098–4102.
Schneider, C. L., and Hudson, A. W.
(2011). The human herpesvirus-
7 (HHV-7) U21 immunoevasin
subverts NK-mediated cytoxicity
through modulation of MICA and
MICB. PLoS Pathog. 7, e1002362.
doi: 10.1371/journal.ppat.1002362
Schrambach, S., Ardizzone, M., Ley-
marie, V., Sibilia, J., and Bahram,
S. (2007). In vivo expression pattern
of MICA and MICB and its rele-
vance to auto-immunity and cancer.
PLoS ONE 2, e518. doi: 10.1371/jour-
nal.pone.0000518
Schwinn, N., Vokhminova, D., Sucker,
A., Textor, S., Striegel, S., Moll, I.,
Nausch, N., Tuettenberg, J., Steinle,
A., Cerwenka, A., Schadendorf, D.,
and Paschen, A. (2009). Interferon-
gamma down-regulates NKG2D lig-
and expression and impairs the
NKG2D-mediated cytolysis of MHC
class I-deﬁcient melanoma by nat-
ural killer cells. Int. J. Cancer 124,
1594–1604.
Simons, M., and Raposo, G. (2009).
Exosomes – vesicular carriers for
intercellular communication. Curr.
Opin. Cell Biol. 21, 575–581.
Snyder, M. R., Weyand, C. M., and
Goronzy, J. J. (2004). The double
life of NK receptors: stimulation or
co-stimulation? Trends Immunol. 25,
25–32.
Steinle, A., Li, P., Morris, D. L.,
Groh, V., Lanier, L. L., Strong, R.
K., and Spies, T. (2001). Interac-
tions of human NKG2D with its lig-
ands MICA, MICB, and homologs
of the mouse RAE-1 protein family.
Immunogenetics 53, 279–287.
Stephens, H. A. (2001). MICA and
MICB genes: can the enigma of their
polymorphism be resolved? Trends
Immunol. 22, 378–385.
Stern-Ginossar, N., Gur, C., Biton,
M., Horwitz, E., Elboim, M., Stani-
etsky, N., Mandelboim, M., and
Mandelboim, O. (2008). Human
microRNAs regulate stress-induced
immune responses mediated by the
receptor NKG2D. Nat. Immunol. 9,
1065–1073.
Strong, R. K., and McFarland, B.
J. (2004). NKG2D and related
immunoreceptors. Adv. Protein
Chem. 68, 281–312.
Suarez-Alvarez, B., Lopez-Vazquez,
A., Diaz-Molina, B., Bernardo-
Rodriguez, M. J., Alvarez-Lopez, R.,
Pascual, D., Astudillo, A., Martinez-
Borra, J., Lambert, J. L., Gon-
zalez, S., and Lopez-Larrea, C.
(2006). The predictive value of sol-
uble major histocompatibility com-
plex class I chain-related molecule
A (MICA) levels on heart allo-
graft rejection. Transplantation 82,
354–361.
Takaki, R., Hayakawa, Y., Nelson, A.,
Sivakumar, P. V., Hughes, S., Smyth,
M. J., and Lanier, L. L. (2005). IL-
21 enhances tumor rejection through
a NKG2D-dependent mechanism. J.
Immunol. 175, 2167–2173.
Thomas, M., Boname, J. M., Field,
S., Nejentsev, S., Salio, M., Cerun-
dolo, V., Wills, M., and Lehner, P. J.
(2008). Down-regulation of NKG2D
and NKp80 ligands by Kaposi’s
sarcoma-associated herpesvirus K5
protects against NK cell cytotoxic-
ity. Proc. Natl. Acad. Sci. U.S.A. 105,
1656–1661.
Upshaw, J. L., Arneson, L. N., Schoon,
R. A., Dick, C. J., Billadeau, D.
D., and Leibson, P. J. (2006).
NKG2D-mediated signaling requires
a DAP10-bound Grb2-Vav1 inter-
mediate and phosphatidylinositol-3-
kinase in human natural killer cells.
Nat. Immunol. 7, 524–532.
Vales-Gomez, M., Browne, H., and
Reyburn, H. T. (2003). Expression
of the UL16 glycoprotein of human
cytomegalovirus protects the virus-
infected cell from attack by natural
killer cells. BMC Immunol. 4, 4. doi:
10.1186/1471-2172-4-4
Vales-Gomez, M., Chisholm, S. E.,
Cassady-Cain, R. L., Roda-Navarro,
P., and Reyburn, H. T. (2008). Selec-
tive induction of expression of a
ligand for the NKG2D receptor by
proteasome inhibitors. Cancer Res.
68, 1546–1554.
Vales-Gomez, M., Winterhalter, A.,
Roda-Navarro, P., Zimmermann, A.,
Boyle, L., Hengel, H., Brooks, A., and
Reyburn, H. T. (2006). The human
cytomegalovirus glycoprotein UL16
trafﬁcs through the plasma mem-
brane and the nuclear envelope. Cell.
Microbiol. 8, 581–590.
Van Belle, T. L., and von Herrath, M.
G. (2009). The role of the activating
receptor NKG2D in autoimmunity.
Mol. Immunol. 47, 8–11.
Verneris, M. R., Karami, M., Baker,
J., Jayaswal, A., and Negrin, R. S.
(2004). Role of NKG2D signaling
in the cytotoxicity of activated and
expanded CD8+ T cells. Blood 103,
3065–3072.
Viaud, S., Terme, M., Flament, C., Taieb,
J., Andre, F., Novault, S., Escud-
ier, B., Robert, C., Caillat-Zucman,
S., Tursz, T., Zitvogel, L., and Cha-
put, N. (2009). Dendritic cell-derived
exosomes promote natural killer cell
activation and proliferation: a role for
NKG2D ligands and IL-15Rα. PLoS
ONE 4, e4942. doi: 10.1371/jour-
nal.pone.0004942
Waldhauer, I., and Steinle, A. (2006).
Proteolytic release of soluble UL16-
binding protein 2 from tumor cells.
Cancer Res. 66, 2520–2526.
Welte, S. A., Sinzger, C., Lutz, S.
Z., Singh-Jasuja, H., Sampaio, K.
L., Eknigk, U., Rammensee, H.
G., and Steinle, A. (2003). Selec-
tive intracellular retention of virally
induced NKG2D ligands by the
human cytomegalovirus UL16 gly-
coprotein. Eur. J. Immunol. 33,
194–203.
Wiemann, K., Mittrucker, H. W., Feger,
U., Welte, S. A., Yokoyama, W. M.,
Spies, T., Rammensee, H. G., and
Steinle, A. (2005). Systemic NKG2D
down-regulation impairs NK and
CD8 T cell responses in vivo. J.
Immunol. 175, 720–729.
Wolan, D. W., Teyton, L., Rudolph, M.
G., Villmow, B., Bauer, S., Busch, D.
H., and Wilson, I. A. (2001). Crys-
tal structure of the murine NK cell-
activating receptor NKG2D at 1.95 A.
Nat. Immunol. 2, 248–254.
Wu, J., Song, Y., Bakker, A. B., Bauer,
S., Spies, T., Lanier, L. L., and
Phillips, J. H. (1999). An activating
immunoreceptor complex formed by
NKG2D and DAP10. Science 285,
730–732.
Wu, J. D., Higgins, L. M., Steinle,
A., Cosman, D., Haugk, K., and
Plymate, S. R. (2004). Prevalent
expression of the immunostimu-
latory MHC class I chain-related
molecule is counteracted by shedding
in prostate cancer. J. Clin. Invest. 114,
560–568.
Yadav, D., Ngolab, J., Lim, R. S., Krish-
namurthy, S., and Bui, J. D. (2009).
Cutting edge: down-regulation
of MHC class I-related chain A
on tumor cells by IFN-gamma-
induced microRNA. J. Immunol. 182,
39–43.
Zhang, C., Niu, J., Zhang, J., Wang,
Y., Zhou, Z., and Tian, Z. (2008).
Opposing effects of interferon-
alpha and interferon-gamma on the
expression of major histocompatibil-
ity complex class I chain-related
A in tumors. Cancer Sci. 99,
1279–1286.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 11 July 2012; accepted: 07
September 2012; published online: 25
September 2012.
Citation: Fernández-Messina L, Reyburn
HT and Valés-Gómez M (2012) Human
NKG2D-ligands: cell biology strategies
to ensure immune recognition. Front.
Immun. 3:299. doi: 10.3389/ﬁmmu.
2012.00299
This article was submitted to Frontiers in
NK Cell Biology, a specialty of Frontiers
in Immunology.
Copyright © 2012 Fernández-Messina,
Reyburn and Valés-Gómez. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion License, which permits use, distri-
bution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
www.frontiersin.org September 2012 | Volume 3 | Article 299 | 9
